Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.
Purpose: Lithium (Li), the first-line treatment of bipolar disorder, was first developed as an immediate-release form with a routine therapeutic drug monitoring 12 h after the last dose. In Europe, the most commonly prescribed form is a sustained release (srLi). Yet no pharmacokinetics (PK) study ha...
| Published in: | European Journal of Clinical Pharmacology Vol. 75; no. 4; pp. 519 - 529 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Springer Nature
Apr2019
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135501936&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 135501936 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Apr2019 vid: 75 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 135501936 135501936 135501936 10.1007/s00228-018-2605-3 135501936 ppf: 519 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. aug: au: Couffignal, C. Bertrand, J. Sportiche, S. Jarroir, Marine El Balkhi, S. Djebrani-Oussedik, N. Poupon, J. Declèves, X. Mentré, F. Bellivier, F. affil: Département de Biostatistique, AP-HP, HUPNVS, 46 rue Henri Huchard, 75877, Paris Cedex 18, France sug: subj: Bipolar Disorder Drug Therapy Lithium Pharmacokinetics Delayed-Action Preparations Pharmacokinetics Human Adult France Lithium Administration and Dosage Lithium Blood Lithium Urine Erythrocytes Drug Effects Population Health Algorithms Utilization Monitoring, Physiologic Models, Biological Computer Simulation Record Review Adult: 19-44 years ab: Purpose: Lithium (Li), the first-line treatment of bipolar disorder, was first developed as an immediate-release form with a routine therapeutic drug monitoring 12 h after the last dose. In Europe, the most commonly prescribed form is a sustained release (srLi). Yet no pharmacokinetics (PK) study has been published of srLi, administered once a day, in adults. The present study describes srLi PK in the serum and erythrocytes of bipolar patients.Methods: To assess srLi PK, we studied prospectively 17 French bipolar patients on a median dose of 1000 mg (600-1600) for at least 2 years. Serum (S), erythrocyte (E) concentrations, and urinary (U) amount were collected over 8 h after 15 days of morning intake using monitoring electronic medical system (MEMs). Population PK parameters were estimated using the SAEM algorithm (MONOLIX 4.3.3 software).Results: Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h−1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h−1, ClES = 9.46 L h−1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.Conclusion: This is a PK model of srLi once a day in bipolar patients using a population approach simultaneously describing Li concentrations in serum, erythrocytes, and urine which provide an estimate of the ratio of concentration in erythrocyte over serum and its between-subject variability (BSV). pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|